Sign In
Buy BCRX
$9.31
+0.170 (+1.86%)
At Close: Jun 23, 2026
BioCryst Pharmaceuticals: Management's Plans For Multibillion HAE Franchise Add Up
01:59pm, Monday, 15'th Jun 2026
BioCryst Pharmaceuticals, Inc. is upgraded to Buy, reflecting strong execution in HAE and a compelling pipeline with Orladeyo and navenibart. BCRX targets $1.8bn in revenues and $1bn in cash by 2033,
— Growing body of ORLADEYO ® clinical data and real-world evidence demonstrates consistent reductions in HAE attack burden and healthcare utilization across diverse patient populations
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Tuesday, 09'th Jun 2026
RESEARCH TRIANGLE PARK, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted n
RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present seven abstracts from its hereditary angioede
BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026
07:00am, Wednesday, 13'th May 2026
RESEARCH TRIANGLE PARK, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present new real-world evidence at the 2026 Internat
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
07:20pm, Tuesday, 12'th May 2026
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
These Analysts Revise Their Forecasts On BioCryst Pharma After Q1 Earnings
01:46pm, Thursday, 07'th May 2026
BioCryst Pharmaceuticals Inc (NASDAQ:BCRX) reported upbeat earnings for the first quarter on Wednesday.
BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2026 Earnings Call Transcript
12:11pm, Wednesday, 06'th May 2026
BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2026 Earnings Call Transcript
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue Estimates
10:30am, Wednesday, 06'th May 2026
BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of $0.06. This compares to break-even earnings per share a year ago.
BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update
07:00am, Wednesday, 06'th May 2026
— Q1 2026 ORLADEYO ® net revenue of $148.3 million (+11% y-o-y; +21% y-o-y on comparable basis excluding European revenue) —
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Tuesday, 05'th May 2026
RESEARCH TRIANGLE PARK, N.C., May 05, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted si
— BioCryst grants Irish affiliate of Neopharmed Gentili exclusive license to commercialize navenibart for hereditary angioedema in Europe —
BioCryst to Present at Upcoming Investor Conferences
07:00am, Tuesday, 28'th Apr 2026
RESEARCH TRIANGLE PARK, N.C., April 28, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company plans to present at the following conferences:
BioCryst to Report First Quarter 2026 Financial Results on May 6
07:00am, Wednesday, 15'th Apr 2026
RESEARCH TRIANGLE PARK, N.C. , April 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2026 financial results o
BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer
07:00am, Monday, 06'th Apr 2026
— Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval —
